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SUMMARY Patients with atopic disorders present an increased 
production of IgE, which is usually limited to speciﬁc antibodies 
against various environmental allergens. It has also been 
suggested that the production of these antibodies may be 
inﬂuenced by effective speciﬁc immunotherapy (SIT). Of course, 
a decline of serum antigen speciﬁc IgE in the course of such 
a treatment cannot explain the clinical efﬁcacy of SIT and is 
probably not a key mechanism. However, SIT may at least 
participate in the ﬁnal clinical result.
 In this study, 37 patients with atopic dermatitis were treated 
with allergy vaccines (Novo-Helisen Depot) for a time period 
of 48 months. The control group consisted of 29 patients with 
atopic dermatitis who were treated with classical methods. The 
clinical score (W-AZS), total IgE and antigen speciﬁc IgE (asIgE) 
in the sera of patients were assessed before treatment and after 
24 and 48 months of therapy (FEIA CAP System, Pharmacia). 
There was a signiﬁcant difference between the two investigated 
groups from both the clinical and immunological standpoints 
after 2 and 4 years of observation. There was a signiﬁcant 
decrease of serum total IgE and asIgE (directed against airborne 
allergens) in the course of speciﬁc immunotherapy. In the control 
group, the total IgE level tended to increase, and this tendency 
was also recorded in case of asIgE measurements. We also 
evaluated the inﬂuence of speciﬁc immunotherapy on the serum 
level of IFN-γ, sIL-2R, IL-4, IL-5 and IL-10 before treatment and 
after 4 years of therapy with the quantitative 2-step colorimetric 
sandwich ELISA method (R&D Systems). 
 In the group of patients treated with allergy vaccines, a 
signiﬁcant decrease of the serum sIL-2R level was observed 
after 48 months of therapy (p<0,01). In the control group, a 
signiﬁcant increase of serum IL-4 (p<0,01) as well as IL-5 
(p<0,05) was registered at the end of the observation period. 
There was no signiﬁcant correlation between the clinical score 
and serum level of any of the investigated cytokines in either 
group of patients before the treatment or after 48 months of 
therapy.
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    Although allergen-speciﬁc immunotherapy (SIT) 
has been widely used for the treatment of allergic 
diseases for more than 90 years, the exact mech-
anism of its action remains to be determined. A 
variety of immunological changes have been de-
scribed during and after clinical courses of SIT, 
and several mechanisms have been proposed for 
SIT’s beneﬁcial clinical effect. However, it remains 
rather unclear which, if any, of these immunologi-
cal changes are involved in the mechanisms by 
which this therapy improves the clinical status of 
patients. 
 Recently, considerable attention has been di-
rected to the mechanisms of SIT. One reason for 
this increased interest is that clariﬁcation of the 
immunological mechanisms underlying the clinical 
efﬁcacy of SIT may provide a new understanding 
of the basic mechanisms of human allergic diseas-
es. Of the many different hypotheses, the clinical 
role of serum immunoglobulins and alternations 
in T-cell response are of special interest. Patients 
with allergic disorders present an increased pro-
duction of IgE, which is usually limited to speciﬁc 
antibodies against environmental allergens. IgE 
molecules bind speciﬁcally to receptors located on 
the surface of tissue mast cells and circulating ba-
sophils, which then produce and release several 
potent mediators involved in the clinical manifes-
tations of allergic diseases. Therefore, a decrease 
of antigen speciﬁc IgE (asIgE) could theoretically 
lead to a good clinical course. It may then be sug-
gested that SIT may inﬂuence the production of 
asIgE.  In the 1970s, it was postulated that a re-
duction of asIgE in the sera of patients treated with 
SIT was a major mechanism of this therapeutic 
method. Later, it was demonstrated that the IgE 
response shows an initial increase, followed by a 
gradual decrease, and after several years of SIT or 
asIgE, the serum level may be not affected (1-7). 
It seems that although a decline of serum asIgE in 
the course of SIT cannot explain the clinical efﬁ-
cacy of SIT and is not always a key mechanism in 
clinically successful SIT, it may at least participate 
in the ﬁnal result of this treatment.
 Atopic dermatitis (AD) represents an inﬂamma-
tory skin disorder which has been well known since 
the beginning of the 20th century, but its pathogen-
esis is not yet clearly understood (8). In addition 
to a multifactorially determined genetic predispo-
sition, AD is characterized by various changes in 
humoral and cell-mediated immunity (8-13). Pro-
found immunological alternations in AD may be 
associated with imbalances within the cytokine 
network (14), and the altered production of im-
muno-modulating cytokines may be the cause of 
changes in the immune response, ﬁnally contribut-
ing to the clinical picture of the disease. It seems 
that the development of AD skin lesions results 
from the sequential activation of Th2 and then Th1 
type cells. This process may be at least partially 
controlled by cells in the microenvironment of the 
skin of AD patients. It is therefore important to 
stress that from an immunological standpoint, Th2 
and Th1-type immune responses are not mutually 
exclusive, and human inﬂammatory diseases like 
AD are based on interactions between different 
Th-cell subsets, which may account for the clinical 
characteristics of the disease (15). A considerable 
number of studies published over the last several 
years demonstrated that SIT may inﬂuence the 
deviated immune response of allergic patients in 
a speciﬁc manner and ﬁnally redirect the immune 
system towards normal immunity (16-18). The 
potential underlying mechanism of the repolariza-
tion of T-cell activity towards a Th1 pattern in the 
course of SIT might either be anergy or immune 
deviation. IL-10 seems to be involved in case of 
T-cell anergy. Perhaps the combination of anergy 
and a reactivation step by microenvironmental cy-
tokines occurs, and anergic cells induced by IL-10 
may recover through the inﬂuence of IL-2 and IL-
15 to produce Th0/Th1 cytokines (16).
 In this study, serum total IgE and asIgE directed 
against common airborne allergens were evaluat-
ed in the course of the 4-year SIT in patients with 
AD and airborne allergy. During the course of SIT, 
we also monitored serum levels of IFN-γ, sIL-2R, 
IL-4, IL-5 and IL-10 in order to analyse the possi-
ble inﬂuence of this type of therapy on the cytokine 
release in AD.
MATERIAL AND METHODS
 Two groups of AD patients were investigated in 
this study. The SIT group consisted of 37 patients 
(25 females, 12 males, age range 5-44 years, 
mean age 18 years) with moderate to severe 
disease activity evaluated by the W-AZS index 
(19,20) 94.5 ± 39.7pts. All patients had excoriated 
skin lesions with intensive pruritus. In all cases, 
the IgE-mediated airborne allergy was conﬁrmed 
(clinical evaluation, skin prick tests with aeroaller-
gens, total IgE, and asIgE against aeroallergens). 
seventeen patients were allergic to grass pollen 
allergens, and 6 patients were allergic to grass 
and mugwort pollen allergens. In 14 cases, allergy 
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to house dust mite allergens (Dermatophagoides 
pteronyssinus – Dp and Dermatophagoides fari-
nae – Df) was diagnosed. In this group of patients, 
SIT with Novo-Helisen Depot vaccines was per-
formed for the time period of 4 years. 
 The control group consisted of 29 patients with 
AD (19 females, 10 males, age range 5-41 years, 
mean age 17 years) with moderate to severe dis-
ease activity assessed by the W-AZS index – 86.9 
± 24.0 pts. No signiﬁcant difference in the clini-
cal activity of AD between these two investigated 
groups was detected before treatment. Patients 
selected for the control group ﬁlled all required 
criteria for SIT but did not decide to participate in 
allergy vaccinations. Eleven patients were allergic 
to grass pollen allergens, and 4 were allergic to 
grass and mugwort pollen allergens. In 14 cases, 
allergy to house dust mite allergens (Dp and Df) 
was diagnosed. In this group of patients, conven-
tional methods of treatment were applied for the 
time period of 4 years. 
 •  Speciﬁc immunotherapy
 Novo-Helisen Depot allergy vaccines were used 
in the treatment of the SIT group. The composition 
of vaccines was individually selected according to 
the clinical and allergological characteristics of pa-
tients. The following allergy vaccines were used:
 1. grass pollen allergens 100% in 17 cases
 2. grass pollen allergens 80% mugwort pollen 
    allergens 20% in 6 patients
 3. house dust mite allergens Dp 50% and Df 
    50% in 14 cases
 • Conventional treatment consisted of anti-
histaminic drugs (I and II generation), antipruritic 
agents, antiinﬂammatory agents, topical steroids, 
moisturizing and greasing agents.
 • Clinical assessment in both investigated 
groups was performed before treatment and after 
12, 24, 36 and 48 months of treatment. The W-
AZS index was used for the clinical evaluation of 
patients (Tables 1 and 2).
 •  Measurement of serum total IgE and asIgE 
by the FEIA-CAP System technique (Pharmacia) 
was performed before treatment and after 24 and 
48 months of treatment in both investigated groups 
of patients.
     
A. PRURITUS EVALUATION:        
                             POINTS 




1.  Single or multiple localization of pruritus................................................................ 2 
2.  Extensive pruritus involving the whole body surface.............................................. 6 
Frequency:
1.  Short episodes of pruritus - less than 30 minutes ................................................. 2 
2.  Long-lasting pruritic episodes ...............................................................................   4 
3.  Constant pruritus   ................................................................................................ 8 
Severity:
1.  Scratching is not necessary  ................................................................................. 2 
2.  Scratching is necessary  ....................................................................................... 4 
3.  Anxiety and irritation caused by pruritus ............................................................... 8 
 
B. LOSS OF SLEEP EVALUATION:
1.  No loss of sleep  ...................................................................................................   0   
2.  Problems in falling asleep  ...................................................................................    3 
3.  Night awakening caused by pruritus ....................................................................    6  
4.  Sleeplessness  ....................................................................................................    12 
  
             I = A + B
W-AZS INDEX
Table 1.
 I. EVALUATION OF PRURITUS AND LOSS OF SLEEP IN PATIENTS WITH ATOPIC DERMATITIS
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 •  Measurement of IFN-γ, sIL-2R, IL-4, IL-5 and 
IL-10 serum levels
 In both investigated groups of AD patients, se-
rum levels of selected cytokines were measured 
before the treatment and after 4 years of therapy 
by a colorimetric ELISA-Quantikine technique us-
ing a quantitative 2-step colorimetric sandwich 
ELISA (R&D System).
Statistical analysis
 Statistical evaluations were performed by using 
the Student’s t-test, ANOVA/MANOVA polydimen-
sional analysis, Wilcoxon test and Mann-Whitney’s 
U test. For an evaluation of correlations, Spear-
man’s rank correlation coefﬁcient was calculated 
for statistical signiﬁcance.
RESULTS
 •  Clinical assessment
 The results of the clinical evaluation of AD pa-
tients are presented in Table 3. From a clinical 
standpoint, there was no signiﬁcant difference 
between the investigated groups before treat-
ment. After 48 months of treatment, the mean 
value of W-AZS in the SIT group declined signiﬁ-
cantly (p<0.001). The clinical picture of patients 
in the control group also improved signiﬁcantly 
(p<0.001). However, statistical analysis performed 
in order to compare the clinical efﬁcacy of SIT and 
conventional methods showed a signiﬁcant dif-
ference after 12, 24, 36 and 48 months of treat-
ment, indicating a better efﬁcacy of SIT (p<0.01; 
p<0.001; p<0.001; p<0.001 respectively). 
  Extensiveness of skin lesions    A   
Severity of skin inﬂammation     
erythema      vesicles         crusts       lichenisation    B
oedema        erosions        scaling     pigmentation
 A x B 
   10        
 1.   Face and neck  
 2.   Scalp and nucha  
 3.   Trunk
       (anterial surface)   
 4.   Trunk         
       (posterial surface)
 5.   Right arm
 6.   Right forearm  
       and hand
 7.   Left arm
 8.   Left forearm
       and hand
 9.   Right thigh
10.  Right shank 
       and foot
11.  Left thigh
12.  Left shank
       and foot
(  )x1=    .....    
(  )x1=    .....
(  )x4=    .....
(  )x4=    .....
(  )x1=    .....
(  )x1=    .....
(  )x1=    .....
(  )x1=    .....
(  )x2=    .....
(  )x2=    .....
(  )x2=    .....
(  )x2=    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....   
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   .....
   .....
   .....
   .....
   .....
   .....
   .....
   .....
   .....
   .....
   .....  
                                                                         TOTAL      II
• Score extensiveness of skin lesions from 0 to 3:      •  Score severity of skin  inﬂammation from 0 to 3:
       0 = not present            0 = not present
         1 = 1-10% of skin surface involved   1 = mild
         2 = 11-30% of skin surface involved   2 = moderate
         3 = 31-100% of skin surface involved  3 = severe
                                                                 TOTAL W-AZS : I + II 
W-AZS INDEX
Table 2.
II. EVALUATION OF EXTENSIVENESS AND SEVERITY OF SKIN  INFLAMMATION IN PATIENTS WITH 
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Mean value of total IgE (KU/l) ± SD
SIT group Control Group
Before treatment                                a  2691.9 ± 3984.1 1839.6 ±  962.7
After 24 months of treatment             b 805.9  ± 732.2  2013.6 ± 128.8
After 48 months of treatment             c  71.,8 ± 669.2  2586.1 ± 1223.4
SIT Group Control Group
a/b - p<0.001 a/b; a/c; b/c – N.S.
a/c - p<0.001
Table 4. Mean serum IgE level (KU/l) ± SD in the SIT group (n-37) and in the control group (n-29) in the 
course of therapy
 •  Serum total IgE level
 The mean serum total IgE decreased signiﬁ-
cantly after 48 months of treatment with allergy 
vaccines (p<0.001). It also decreased in the con-
trol group, but the difference was not statistically 
signiﬁcant (Table 4). Statistical analysis performed 
in order to compare this parameter in both investi-
gated groups showed that before treatment there 
was no signiﬁcant difference between the SIT and 
control groups. On the other hand, after 24 and 
48 months of treatment, there was a signiﬁcant 
difference between the two investigated groups 
(p<0.001) to the advantage of the SIT patients.
 •  asIgE serum level
 Fourteen patients in the SIT group were allergic 
to d1(Dp) and d2 (Df). The mean serum level of 
asIgE against d1 and d2 decreased signiﬁcantly 
after 48 months of treatment (p<0.001) (Table 5). 
In the control group, the mean serum level of 
asIgE against d1 and d2 also decreased during 48 
months of conventional therapy, but the difference 
was not signiﬁcant (Table 5). Comparative statisti-
cal analysis showed no signiﬁcant differences be-
tween the SIT and control groups before treatment. 
After 24 months of therapy, however, a signiﬁcant 
difference was detected between the asIgE mea-
surement results of the investigated groups, d1 
– p<0.01 and d2 – p<0.01 to the advantage of the 
SIT group. In addition, after 48 months of therapy, 
a signiﬁcant difference was found between the 
groups: d1 – p<0.001 and d2 – p< 0.001.
 Seventeen patients in the SIT group and 11 pa-
tients in the control group were allergic to grass 
pollen allergens: g3 - cocksfoot, g4 - meadow 
fescue, g5 – rye grass, g6 – timothy grass, g12 
– cultivated rye. The mean serum levels of asIgE 
against grass pollen allergens are presented in 
Table 6. In the SIT group, the mean serum level of 
asIgE against selected grass pollen allergens was 
signiﬁcantly lower after 48 months of treatment 
than before treatment  (g3: p<0.001, g4: p<0.05, 
g5: p<0.001, g6: p<0.001, g12: p<0.001). In the 
control group, the mean serum level of asIgE 
  Table 3. Mean value of W-AZS index ± SD before treatment and after 12, 24, 36 and 48 months of 
therapy in both investigated groups





Before treatment                            a 94.5 ± 39.7 86.9 ± 24.0
After 12 months of treatment         b 37.5 ± 30.4 56.0 ± 22.8
After 24 months of treatment         c 18.4 ± 17.6 53.3 ± 27.4
After 36 months of treatment         d 12.8 ± 17.1 45.4 ± 22.0
After 48 months of treatment         e 11.1 ± 19.1 47.2 ± 25.3
SIT Group Control Group
a/b – p<0.01 a/b; a/c; a/d; a/e – p<0.001
a/c; a/d; a/e – p<0.001
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against selected grass pollen allergens decreased 
signiﬁcantly after 48 months of therapy only in case 
of g3 and g4 (p<0.01 and p<0.05 respectively). 
Statistical comparative analysis of the results of 
asIgE measurements performed before treatment 
between the SIT and control groups showed no 
signiﬁcant difference. On the other hand, after 24 
and 48 months of therapy there was a signiﬁcant 
difference between these groups to the advantage 
of the SIT group. After 24 months of therapy: g3 – 
p<0.0001; g4, g5, g6, g12 – p<0.001, and after 48 
months of therapy: g3, g4, g5, g6, g12 – p<0.001.
Table 5. Mean serum level of serum asIgE against house dust mite allergens in the SIT group (n-14) and 
in the control group (n-14).
Mean value of antigen specific IgE (KU/l) ± SD
SIT Group Control Group
d1 d2 d1 d2
Before treatment                       a 244.7 ± 320.4 255.2 ± 268.7 222.3 ± 269.2 251.0 ± 241.8
After 24 months of treatment    b 101.4 ± 203.9 87.9 ± 150.2 217.9 ± 268.5 255.0 ± 235.2
After 48 months of treatment    c 32.2± 41.4 27.5 ± 33.4 207.7 ± 246.4 229.2 ± 209.9
d1 – Dermatophagoides pteronyssinus
d2 – Dermatophagoides farinae
SIT Group
d1: a/b – p<0.01
      a/c – p<0.001
d2: a/b – p<0.05
      a/c – p<0.001
Control Group
d1: a/b; a/c - N.S.
d2: a/b; a/c - N.S.
Table 6. Mean serum level of as IgE against grass pollen allergens in the SIT group (n-17) and in the 
control group (n-11)
Mean value of antigen specific IgE (KU/l) ± SD
SIT Group
g3 g4 g5 g6 g12
Before treatment                       a 121.3 ± 95.3 143.1 ±  158.6 128.0 ± 152.7 139.9 ± 177.7 143.9 ± 185.0
After 24 months of treatment    b 40.9 ± 34.3 44.4 ±  37.9 35.6 ± 27.7 36.4 ± 32.6 37.7 ± 34.4
After 48 months of treatment    c 20.4 ± 22.0 20.0 ± 22.0 20.7 ± 19.4 19.0 ± 20.6 17.4 ± 17.3
Control Group
g3 g4 g5 g6 g12
Before treatment                       a 143.7 ± 50.7 149.1 ± 46.6 138.0 ± 51.4 140.0 ± 70.9 110.4 ± 40.4
After 24 months of treatment    b 186.0 ± 66.9 182.4 ± 73.9 142.5 ± 49.9 176.8 ± 79.6 133.6 ± 54.6
After 48 months of treatment    c 196.2 ± 85.7 194.7 ± 65.3 156.3 ± 54. 2 170.8 ± 70.1 128.6 ± 50.7
SIT Group
g3: a/b – p<0.05
      a/c – p<0.001
g4: a/b – N.S.
      a/c – p<0.001
g5: a/b – p<0.05
      a/c – p<0.001
g6: a/b – p<0.05
      a/c – p<0.001 
g12: a/b – p<0.05     
        a/c – < 0.001
Control Group
g3: a/b; a/c – p<0.01
g4: a/b; a/c – p<0.05
g5: a/b; a/c – N.S.
g6: a/b; a/c – N.S.
g12: a/b; a/c – N.S.
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  six patients in the SIT group and 4 patients in 
the control group were allergic to grass pollens and 
mugwort pollen allergens (w6). The mean serum 
level of asIgE against these allergens is presented 
in Table 7. After 48 months of treatment with aller-
gy vaccines, we recorded a signiﬁcant decrease 
of asIgE directed against g5 and w6 (p<0.05 and 
p<0.01 respectively). In the control group, a signif-
icant decline was observed in case of g3, g6 and 
g12 after 48 months of therapy (p<0.001, p<0.05 
and p<0.05 respectively). Comparative statisti-
cal analysis of measurements of serum as IgE 
performed between the SIT and control groups 
indicated that there was no signiﬁcant difference 
before treatment. After 48 months of therapy, how-
ever,  signiﬁcant differences were found in case 
of g3 (p<0.05), g4 (p<0.01), g5 (p<0.05) and g12 
(p<0.05) to the advantage of the SIT group. In 
case of g6 and w6, there was no signiﬁcant differ-
ence after both 24 and 48 months of therapy. 
 • Correlational analysis between the clinical 
score and the results of total IgE and asIgE mea-
surements
 In the global population of AD patients inves-
tigated in this study (the SIT and control groups), 
there was a signiﬁcant correlation before treat-
ment between the clinical score assessment and 
total serum IgE measurements (p<0.001) (Fig. 1). 
After 48 months of treatment, a signiﬁcant corre-
lation between the above-mentioned parameters 
was found in the SIT group (p<0.01) (Fig. 2). 
There was no signiﬁcant correlation between the 
clinical score and serum asIgE measurements in 
either investigated group before treatment or after 
48 months of therapy. 
Serum levels of selected cytokines (Table 8)
 • IFN-γ
 In the SIT and control groups, the mean se-
rum level of IFN-γ increased  during 48 months of 
treatment but with no statistical signiﬁcance. Also, 
there was no signiﬁcant difference between the 
two investigated groups either before treatment or 
after 4 years of therapy.
 • sIL-2R
 The mean serum level of sIL-2R in the SIT 
group decreased signiﬁcantly after 4 years of 
therapy (p<0.01). It also decreased in the control 
group but with no signiﬁcant difference. There was 
Table 7. Mean serum level of as IgE against grass and mugwort pollen allergens in the SIT group (n-6) 
and control group (n-4)
Mean value of antigen specific IgE (KU/l) ± SD
SIT Group
g3 g4 g5 g6 g12 w6
Before treatment    a 35.5 ± 28.3 39.0 ± 34.3 53.9 ± 52.4 56.7 ± 80.2 38.9 ± 39.5 37.3± 33.8
After 24 months of 
treatment    b 66.7± 107.8 47.7 ± 47.5 47.5 ± 63.3 64.4 ± 104.6 36.9 ± 42.2 28.2± 57.3
After 48 months of 
treatment    c 29.3 ± 45.2 26.1 ± 31.5 24.6± 31.2 26.4 ± 42.9 23.3± 35.8 14.0± 30.3
Control Group
g3 g4 g5 g6 g12 w6
Before treatment    a 48.8 ± 39.9 40.0 ± 24.1 44.0 ± 29.7 38.3 ± 27.1 45.0 ± 14.2 43.0± 19.0
After 24 months of 
treatment    b 82.3 ± 50.0 57.9 ± 32.3 62.2 ± 10.3 54.5 ± 18.7 82.6 ± 11.7 37.8± 20.6
After 48 months of 
treatment    c 103.6± 36.9 77.0 ± 16.4 80.4 ± 36.1 68.9 ± 22.2 102.4± 39.7 36.1± 21.4
SIT Group
g3:  a/b; a/c - N.S. 
g4:  a/b; a/c - N.S.  
g5:  a/c - p < 0.05 
       a/b -  N.S.
g6:  a/b; a/c - N.S. 
g12: a/b; a/c - N.S.
w6:  a/c -  p < 0.01 
        a/b - N.S.
Control Group
g3: a/b; a/c - p < 0.001
g4: a/b; a/c – N.S.
g5: a/b; a/c – N.S.
g6: a/b – N.S.  
      a/c - p < 0.05
g12: a/b; a/c –  p < 0.05
w6:  a/b; a/c – N.S. 
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no signiﬁcant difference between the two investi-
gated groups of AD either before or after 4 years 
of therapy.
 • IL-4
 In the group of SIT patients, the mean serum 
level of IL-4 after 4 years of therapy slightly de-
creased, while it increased signiﬁcantly in the con-
trol group (p<0.01). There was no signiﬁcant dif-
ference between the SIT and control groups either 
before treatment or after 4 years of therapy.
 • IL-5
 The mean serum level of IL-5 in the SIT group 
slightly increased after 4 years, and in the control 
group it increased signiﬁcantly (p<0.05). There 
was no signiﬁcant difference between patients 
treated with SIT and patients in the control group 
either before or after 48 months of therapy.
 • IL-10
 Patients treated with SIT and conventional 
therapy presented a slight increase in their IL-10 
level after 4 years of treatment. There was also no 
signiﬁcant difference between the two investigat-
ed groups either before or after 4 years of therapy 
(Table 7).
 • Correlation between serum IFN-γ, sIL-2R, IL-
4, IL-5 and IL-10 levels and the clinical score
 There was no signiﬁcant correlation among the 
serum levels of IFN-γ, sIL-2R, IL-4, IL-5 and IL-10 
in the two investigated groups of AD patients either 
before treatment or after 48 months of therapy. No 
signiﬁcant correlation between the clinical score 
(W-AZS) and measurements of serum cytokines 
levels was found in either the SIT or control group 
before treatment or after 48 months of therapy. 
DISCUSSION
 AD patients selected for the study presented 
high serum levels of total IgE and asIgE against 
aeroallergens. Therefore, it was indicated that 
Table 8. Mean serum levels of selected cytokines (pg/ml) ± SD in atopic dermatitis patients before treat-
ment and after 48 months of therapy in the SIT group (n-37) and in the control group (n-29) 
Mean serum level of selected cytokines (pg/ml) ± SD
SIT Group
IFN-γ sIL-2R IL-4 IL-5 IL-10
Before treatment 9.3 ± 16.7 2090 ± 897.9 25.1 ± 37.7 0.5 ± 1.4 5.2 ± 4.8
After 48 months of 
treatment 27.1 ± 62.4 1798.5± 624.6 20.6 ± 29.0 0.8 ± 2.4 5.6 ± 7.0
Control Group
IFN-γ sIL-2R IL-4 IL-5 IL-10
Before treatment 8.9 ± 18.4 1929.6± 703.8 22.5 ± 30.7 0.3 ± 1.1 3.1 ± 3.7
After 48 months of 
treatment 19.8 ± 46.0 1617.5± 446.0 28.7 ± 31.9 0.9 ± 2.6 3.7 ± 3.3
Figure 1. Correlation between total IgE measure- 
ments and the clinical score (W-AZS) in the global 
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Figure 2. 
Corr lation between total IgE measurements and the clinical score (W-AZS) in 
the SIT group of AD patients (n-37) after 48 months of therapy (p<0.01) 
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Corr.coeff. = 0.4951
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Figure 2. Correlation between total IgE measure- 
ments and the clinical score (W-AZS) in the SIT 
group of AD patients (n-37) after 48 months of 
therapy (p<0.01)
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IgE-mediated allergy was involved in the develop-
ment of their skin lesions. Patients in the SIT group 
and in the control group were highly comparable 
from both the clinical (W-AZS index score) and al-
lergological standpoints (total IgE, asIgE serum 
levels). Thus, the impact of different methods of 
treatment on the mentioned parameters could be 
assessed. In the group of SIT patients, a gradual 
decline in the mean total IgE level was recorded in 
the course of the 4 year treatment, which was es-
pecially noticeable after the ﬁrst year of SIT. After 
both 2 and 4 years of treatment with allergy vac-
cines, the serum total IgE measurements were sig-
niﬁcantly lower for SIT patients than in the control 
group. Patients treated with conventional methods 
presented a noticeable increase tendency in the 
mean total IgE level. Therefore, the opposite inﬂu-
ence of treatment applied to total serum IgE was 
registered in the two investigated groups. This 
immunological parameter is still considered to be 
very important in about 80% of AD patients with 
an allergic type of the disease, and the decreasing 
inﬂuence of SIT on total IgE should therefore be 
highlighted. 
 In the case of the whole population of AD pa-
tients (the SIT group and the control group), there 
was a signiﬁcant correlation between the clinical 
status of patients and IgE measurements before 
treatment. After 48 months of treatment, a sig-
niﬁcant correlation was recorded only in the SIT 
group It could therefore be concluded that SIT 
modulates the immunological status of AD pa-
tients with noticeable implications on the severity 
of the inﬂammatory process. Various data in the 
literature concerning the correlation between the 
clinical picture of AD patients and the serum total 
IgE level are rather contradictory, although many 
authors have observed that these parameters are 
strongly correlated (21-25). Perhaps these con-
tradictions are related to a different selection of 
patients for investigations and various methods of 
clinical and statistical assessment. 
 The results of asIgE measurements demon-
strated a clear tendency of decrease in the SIT 
group. This was rather expected, as SIT is known 
to result in an initial increase and further decrease 
of serum asIgE levels in atopic patients (26-28). 
However, all available information about the men-
tioned phenomenon are based on studies per-
formed in other than AD atopic diseases. This 
study therefore demonstrated that in AD patients, 
SIT has an effect on asIgE levels similar to the 
effect observed in other investigated atopic dis-
eases. 
In the group of patients allergic to house dust 
mites, a signiﬁcant difference between asIgE mea-
surements before and after 24 and 48 months of 
SIT was observed in case of both d1 and d2 aller-
gens. There was also a decrease of mean serum 
asIgE (d1,d2) in the control group, but no signiﬁ-
cant difference was detected. After both 24 and 48 
months of therapy, asIgE levels against d1 and d2 
in the control group were signiﬁcantly higher than 
in the SIT group. SIT has been previously reported 
by Pacor et al. (29) to decrease the level of asIgE 
against Dp in patients with AD in the course of a 
3-year therapy. On the other hand, Zachariae et 
al. (37) have not recorded any inﬂuence of SIT on 
a group of 12 patients with severe AD during 6 
months of treatment. Perhaps the 6 month period 
of SIT was not sufﬁcient to modulate the level of 
asIgE in a distinct manner, and a prolonged and 
systematic treatment would be necessary for 
this phenomenon to occur. Likewise, Glover and 
Atherton (30) have not registered a decreasing 
impact of SIT on asIgE levels in AD patients al-
lergic to house dust mite allergens. But again, only 
12 weeks of therapy seems to be rather short to 
expect such changes to take place. In the cited in-
vestigation, no signiﬁcant inﬂuence on the results 
of skin prick tests and total IgE serum levels was 
observed, which is contradictory to our results. 
(Skin prick tests in our group of investigated pa-
tients showed a clear tendency for negativization 
– results are not presented in this paper.) 
 In case of monoallergy (Dp), we observe a very 
good clinical efﬁcacy of SIT, and noticeable varia-
tions of clinical score and immunological param-
eters are expected. As mentioned above, how-
ever, a longer period of SIT is required for these 
events to occur. In the group of AD patients al-
lergic to grass pollen allergens and treated with 
Novo-Helisen Depot allergy vaccines, a notice-
able decrease of mean serum asIgE against g3, 
g4, g5, g6 and g12 was observed. On the other 
hand, there was a clear tendency of the asIgE 
mean level in the control group to increase. After 
both 24 and 48 months of therapy, there was a 
signiﬁcant difference of asIgE levels against all in-
vestigated grass pollen allergens between the SIT 
and control groups to the advantage of patients 
treated with allergy vaccines. 
 Patients allergic to grass and mugwort pollen 
allergens reacted to the treatment somewhat dif-
ferently. In fact, it was the smallest group–only 10 
patients (6 in the SIT group and 4 in the control 
group)-and therefore a proper analysis of the re-
sults is rather impossible. At any rate, it is inter-
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esting that in case of g3, g4 and g6, there was 
an increase in the mean serum asIgE level after 
24 months of SIT, which then decreased twofold 
after 48 months of therapy in comparision with the 
mean level of asIgE before treatment. In case of 
asIgE against g5 and g12, a decrease in the mean 
serum levels during the course of treatment was 
observed. Only in case of g12 and w6 a signiﬁ-
cant difference was detected after 24 months of 
SIT in comparison with results obtained before the 
treatment. 
 In the control group, there was a clear tendency 
of the asIgE level against grass pollen allergens 
to increase and the asIgE level against w6 to de-
crease. After 4 years of treatment, there was a sig-
niﬁcant difference in asIgE measurements for all 
grass pollen allergens investigated between the 
SIT and control groups to the advantage of the SIT 
group. Such a difference was detected for w6 after 
both 24 and 48 months of treatment. These results 
indicated that in patients allergic to grass pollen al-
lergens, an additional hypersensivity to w6 created 
a noticeable difference in the course of SIT from 
both the clinical and immunological standpoints. 
It might be related to a polyvalency of allergy, a 
wider exposition to allergens and the complexity of 
allergy vaccines’ composition. Thus, it seems that 
AD patients allergic to grass pollen allergens and 
those who are additionally allergic to w6 should be 
regarded as two different subpopulations. Unfor-
tunately, there are no data in the literature which 
consider this problem, as all investigations on the 
inﬂuence of SIT on asIgE serum levels in AD pa-
tients were performed on populations allergic to 
house dust mites.
 It is also of allergological and clinical interest to 
note whether there are any correlations between 
the clinical severity of the disease and asIgE lev-
els in the sera of patients. No such correlations 
have been detected in either group of AD patients 
in this study, either before treatment or after 24 
and 48 months of treatment.
 Very little is known about cytokine production 
and release in AD patients in the course of SIT. We 
evaluated Th1 and Th2 related cytokines before 
treatment and after 4 years of SIT or conventional 
therapy. No signiﬁcant differences were found be-
tween the two investigated groups of patients ei-
ther before treatment or after 4 years of therapy. 
In  the SIT group, there was a signiﬁcant decrease 
in the serum sIL-2R level after 4 years of therapy, 
clearly indicating an immunomodulatory inﬂuence 
of SIT in AD. The mean serum levels of IL-4 and 
IL-5 increased signiﬁcantly in the control group af-
ter 4 years of treatment. These results provided 
clear evidence that patients with AD react in a dif-
ferent manner to SIT than to conventional meth-
ods of treatment. 
 It is known that AD patients with moderate to 
severe disease activity are characterized by an 
impaired capacity of their T-cells to release IL-2 in 
vitro (31). This deﬁciency may be relatively specif-
ic, since no signiﬁcant changes could be detected 
in patients with severe plaque-type psoriasis. De-
creased IL-2 production may signiﬁcantly corre-
late with the eczematous involvement of patients’ 
skin. It is also documented that T lymphocyte ac-
tivation represents a very complex process, which 
involves a variety of cytokines, including IL-1 
and IL-2 (31). IL-1 is released by monocytes and 
thought to represent one of the accessory cell-de-
rived signals required for efﬁcient T-cell activation. 
In contrast, IL-2 is produced by activated T-cells 
and known to upregulate the expression of its own 
receptor (31). Functional alternations of T-cells 
such as decreased lymphoproliferative responses 
(32-34), could be the result of a diminished capac-
ity of mononuclear cells to release IL-1 and IL-2 
upon appropriate stimulation. It has been shown, 
however, that the sera of AD patients as well as 
psoriasis contained signiﬁcantly increased levels 
of sIL-2R, as compared with healthy controls (35). 
Thus, the ﬁnding of increased sIL-2R levels is in 
apparent conﬂict with decreased lymphoprolifera-
tive responses in vitro. A supposed T-cell defect 
which could be shown by functional assays in the 
peripheral blood is therefore in direct contrast to 
signs of hyperactivation. 
 One possible explanation for the contradictory 
ﬁndings would be that the inﬂammatory process 
in AD is focused on the skin. Therefore, perhaps 
the decreased production of cytokines by blood 
mononuclear cells is due to a down-regulation of 
the immune response in the peripheral blood in-
duced by cytokines released from hyperactivated 
immune cells in the inﬂammed skin. Alternatively, 
the hyporesponsiveness of mononuclear cells in 
vitro could be a sign of “exhaustion” following ex-
cessive stimulation in vivo. These suggestions are 
supported by the ﬁnding that alternations of district 
T-cell functions normalized with clinical remissions 
(33,34,36). 
 It seems that a decrease of sIL-2R serum in the 
course of treatment indicates the clinical improve-
ment of AD patients (37). This phenomenon oc-
curred in both groups of investigated patients, but 
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it was signiﬁcant only in the SIT group. It should 
also be mentioned that a clinical improvement was 
noticed in both the SIT and control groups, but it 
was more distinct on patients treated with allergy 
vaccines. Therefore, it is not surprising to us that 
the sIL-2R serum level decreased more signiﬁ-
cantly in the SIT group. 
 Data in the literature on IL-4 production in AD 
are controversial. Kasamatsu et al. (38) detected 
higher levels of IL-4 in AD patients than in healthy 
controls, while other authors have not conﬁrmed 
this observation (39). In our study, mean levels 
of IL-4 and IL-5 were not higher than the refer-
ence values for healthy controls. In the course of 
treatment in the SIT group, the mean level of IL-4 
decreased slightly and the mean level of IL-5 in-
creased slightly. On the other hand, conventional 
therapy resulted in a signiﬁcant increase of IL-4 
and IL-5 serum levels. IL-10 serum levels were 
characterised by a slight tendency to increase in 
both investigated groups after 4 years of therapy.
 In conclusion, SIT appeared to be an effective 
method of treatment in case of selected patients 
with AD and airborne allergy. The possible appli-
cation of this method in selected cases of AD has 
recently been one of our major interests, and our 
previous clinical results were satisfactory (40-44). 
In the course of SIT, a signiﬁcant decrease of total 
IgE and asIgE against aeroallergens in the sera 
of patients was observed. These observations dif-
ferentiated the SIT group from the control group 
of AD patients treated with conventional methods. 
Although it is not clear what the real role of IgE is 
in the mechanism of successful SIT, it seems that 
IgE deﬁnitely participates in this event not only in 
case of venom allergy or allergic rhinitis but also 
in AD patients treated with allergy vaccines. At the 
moment, it is difﬁcult to properly evaluate the pos-
sible effect of SIT on the release of investigated 
cytokines, but these preliminary results indicate a 
complexity of events occurring in the course of al-
lergy vaccinations in AD. We hope to investigate 
this problem further in the future.
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